Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization.

TitleElevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization.
Publication TypeJournal Article
Year of Publication2021
AuthorsGill CM, AktaƟ E, Alfouzan W, Bourassa L, Brink A, Burnham C-AD, Canton R, Carmeli Y, Falcone M, Kiffer C, Marchese A, Martinez O, Pournaras S, Seifert H, Thabit AK, Villegas MVirginia, Westblade LF, Nicolau DP
Corporate AuthorsERACE-PA Global Study Group
JournalAntimicrob Agents Chemother
Volume65
Issue11
Paginatione0120421
Date Published2021 Oct 18
ISSN1098-6596
Abstract

The present study evaluated the potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints.

DOI10.1128/AAC.01204-21
Alternate JournalAntimicrob Agents Chemother
PubMed ID34398670
Related Faculty: 
Lars Westblade, Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700